{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:20:13Z","timestamp":1788142813719,"version":"build-2803163510"},"reference-count":80,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Although oral peptide drug administration is the most desirable for both patients and healthcare systems, it is a major pharmaceutical challenge. Typically, less than 1% of orally administered peptide therapeutics reaches the systemic circulation. Modern research has focused on overcoming the physiological barriers responsible for the poor peptide drug bioavailability, while little attention has been given to understanding how measurable absorption occurs despite the barriers. This review aimed to explore the physiological factors that influence oral peptide absorption, such as enzymatic degradation and pH effects, motility, microbiota, transporters, tight junctions, and the effect of inflammation. The available data indicate that these factors function not only as barriers but may also create limited opportunities for peptide uptake. Enzymatic degradation and microbial metabolism reduce the availability of intact peptide drugs yet may generate biologically relevant fragments. Tight junctions are generally regarded as restrictive barriers but are shown to exhibit dynamic regulations that may permit transient paracellular transport. Similarly, gastrointestinal motility, microbiota, and inflammatory processes influence epithelial permeability and duration of peptide exposure both to absorptive surfaces and to degradative enzymes. In contrast, transporter-mediated uptake appears unlikely to account for the absorption of intact peptide drugs due to their substrate size limitations. Together, the findings suggest that measurable oral peptide absorption is unlikely to result from a single dominant pathway but rather from the cumulative contribution of the mechanisms. Improved understanding of these endogenous mechanisms may open opportunities to enhance oral peptide bioavailability and support the development of more effective therapeutics.<\/jats:p>","DOI":"10.3390\/pharmaceutics18091091","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:08:58Z","timestamp":1788142138000},"page":"1091","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Natural Oral Absorption of Therapeutic Peptides: Mechanisms and Physiological Determinants"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3331-1006","authenticated-orcid":false,"given":"Lania","family":"Ali Hussein","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Riga Stradins University, LV-1007 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6448-6468","authenticated-orcid":false,"given":"Alexandra","family":"Nedic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Riga Stradins University, LV-1007 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9529-8799","authenticated-orcid":false,"given":"Andrejs","family":"Sitovs","sequence":"additional","affiliation":[{"name":"Leading Research Group, Faculty of Pharmacy, Riga Stradins University, LV-1007 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8771-3470","authenticated-orcid":false,"given":"Valentyn","family":"Mohylyuk","sequence":"additional","affiliation":[{"name":"Leading Research Group, Faculty of Pharmacy, Riga Stradins University, LV-1007 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Rahman, M.S., Hossain, K.S., Das, S., Kundu, S., Adegoke, E.O., Rahman, M.A., Hannan, M.A., Uddin, M.J., and Pang, M.-G. (2021). Role of Insulin in Health and Disease: An Update. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126403"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Al Shaer, D., Al Musaimi, O., Albericio, F., and De La Torre, B.G. (2022). 2021 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals, 15.","DOI":"10.3390\/ph15020222"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/qjmed\/92.1.1","article-title":"Peptides as drugs","volume":"92","author":"Edwards","year":"1999","journal-title":"QJM"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Nicze, M., Bor\u00f3wka, M., Dec, A., Niemiec, A., Bu\u0142dak, \u0141., and Okopie\u0144, B. (2024). The Current and Promising Oral Delivery Methods for Protein- and Peptide-Based Drugs. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25020815"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e1176822","DOI":"10.1080\/21688370.2016.1176822","article-title":"Safety concerns over the use of intestinal permeation enhancers: A mini-review","volume":"4","author":"McCartney","year":"2016","journal-title":"Tissue Barriers"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jconrel.2018.08.032","article-title":"Oral peptide delivery: Translational challenges due to physiological effects","volume":"287","author":"Tyagi","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijpharm.2013.02.030","article-title":"Approaches for enhancing oral bioavailability of peptides and proteins","volume":"447","author":"Renukuntla","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2020.05.007","article-title":"Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches","volume":"157","author":"Brayden","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Baral, K.C., and Choi, K.Y. (2025). Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17040397"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ejpb.2015.05.013","article-title":"Sodium caprate-induced increases in intestinal permeability and epithelial damage are prevented by misoprostol","volume":"94","author":"Brayden","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0169-409X(91)90014-4","article-title":"(B) Mechanisms of peptide and protein absorption: (2) Transcellular mechanism of peptide and protein absorption: Passive aspects","volume":"7","author":"Burton","year":"1991","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0169-409X(91)90013-3","article-title":"(B) Mechanisms of peptide and protein absorption: (1) Paracellular intestinal transport: Modulation of absorption","volume":"7","author":"Nellans","year":"1991","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Khalid, N.-U.-A., Rivera-Delgado, E., and Von Erlach, T. (2026). Navigating the complexity of oral peptide delivery: Challenges and strategies to enhance oral bioavailability. Front. Drug Deliv., 6.","DOI":"10.3389\/fddev.2026.1809842"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8094","DOI":"10.1021\/acs.chemrev.6b00838","article-title":"Orally Absorbed Cyclic Peptides","volume":"117","author":"Nielsen","year":"2017","journal-title":"Chem. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/bip.22878","article-title":"Cyclic peptide oral bioavailability: Lessons from the past","volume":"106","author":"Wang","year":"2016","journal-title":"Biopolymers"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"122004","DOI":"10.1016\/j.ijpharm.2022.122004","article-title":"The Caco-2 Model: Modifications and enhancements to improve efficiency and predictive performance","volume":"624","author":"Panse","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.ddtec.2011.11.006","article-title":"Overcoming poor permeability: Translating permeation enhancers for oral peptide delivery","volume":"9","author":"Maher","year":"2012","journal-title":"Drug. Discov. Today. Technol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"122131","DOI":"10.1016\/j.ijpharm.2022.122131","article-title":"Characterization of the physicochemical interactions between exenatide and two intestinal permeation enhancers: Sodium caprate (C(10)) and salcaprozate sodium (SNAC)","volume":"626","author":"Twarog","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40262-018-0728-4","article-title":"Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes","volume":"58","author":"Granhall","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_21","unstructured":"U.S. Food & Drug Administration (2026, August 18). Drugs@FDA: FDA-Approved Drugs\u2014Rybelsus, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=213051."},{"key":"ref_22","unstructured":"U.S. Food & Drug Administration (2026, August 18). Drugs@FDA: FDA-Approved Drugs\u2014Wegovy, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/CDER\/daf\/index.cfm?event=overview.process&ApplNo=215256."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4103\/ijem.ijem_522_21","article-title":"A Review of Oral Semaglutide Available Evidence: A New Era of Management of Diabetes with Peptide in a Pill Form","volume":"26","author":"Kalra","year":"2022","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s40262-021-01025-x","article-title":"Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials","volume":"60","author":"Overgaard","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.7150\/thno.61747","article-title":"Oral delivery of protein and peptide drugs: From non-specific formulation approaches to intestinal cell targeting strategies","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/35067088","article-title":"Multifunctional strands in tight junctions","volume":"2","author":"Tsukita","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrm.2016.80","article-title":"Tight junctions: From simple barriers to multifunctional molecular gates","volume":"17","author":"Zihni","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"a002584","DOI":"10.1101\/cshperspect.a002584","article-title":"Physiology and Function of the Tight Junction","volume":"1","author":"Anderson","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00109-017-1557-x","article-title":"Layered defense: How mucus and tight junctions seal the intestinal barrier","volume":"95","author":"Capaldo","year":"2017","journal-title":"J. Mol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1091\/mbc.e16-10-0698","article-title":"Visualizing the dynamic coupling of claudin strands to the actin cytoskeleton through ZO-1","volume":"28","author":"Tietgens","year":"2017","journal-title":"Mol. Biol. Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semcdb.2015.04.003","article-title":"Claudin switching: Physiological plasticity of the Tight Junction","volume":"42","author":"Capaldo","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.gastro.2005.05.002","article-title":"Interleukin-13 Is the Key Effector Th2 Cytokine in Ulcerative Colitis That Affects Epithelial Tight Junctions, Apoptosis, and Cell Restitution","volume":"129","author":"Heller","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/gut.2006.094375","article-title":"Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn\u2019s disease","volume":"56","author":"Zeissig","year":"2007","journal-title":"Gut"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.addr.2009.09.006","article-title":"Safety and efficacy of sodium caprate in promoting oral drug absorption: From in vitro to the clinic","volume":"61","author":"Maher","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2213-8587(18)30372-3","article-title":"Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: A randomised, double-blind, phase 2 trial","volume":"7","author":"Halberg","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_36","unstructured":"National Center for Biotechnology Information (2026, June 02). PubChem Compound Summary for CID 118984375, Insulin Human, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Insulin-Human."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12934-014-0141-0","article-title":"Cell factories for insulin production","volume":"13","author":"Baeshen","year":"2014","journal-title":"Microb. Cell Fact."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jconrel.2019.08.008","article-title":"Labrasol\u00ae is an efficacious intestinal permeation enhancer across rat intestine: Ex vivo and in vivo rat studies","volume":"310","author":"McCartney","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"124353","DOI":"10.1016\/j.ijpharm.2024.124353","article-title":"Labrafac\u2122 MC60 is an efficacious intestinal permeation enhancer for macromolecules: Comparisons with Labrasol\u00ae ALF in ex vivo and in vivo rat studies","volume":"661","author":"McCartney","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"105737","DOI":"10.1016\/j.ejps.2021.105737","article-title":"Sodium glycodeoxycholate and sodium deoxycholate as epithelial permeation enhancers: In vitro and ex vivo intestinal and buccal bioassays","volume":"159","author":"Brayden","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1023\/A:1018819012405","article-title":"Biopharmaceutical Approaches for Developing and Assessing Oral Peptide Delivery Strategies and Systems: In Vitro Permeability and In Vivo Oral Absorption of Salmon Calcitonin","volume":"16","author":"Sinko","year":"1999","journal-title":"Pharm. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jconrel.2025.01.013","article-title":"Design, evaluation, and in vitro\u2013in vivo correlation of self-nanoemulsifying drug delivery systems to improve the oral absorption of exenatide","volume":"379","author":"Venkatasubramanian","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"25689","DOI":"10.1021\/acs.jmedchem.5c02276","article-title":"Overcoming Challenges in the Metabolism of Peptide Therapeutics: Strategies and Case Studies for Clinical Success","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1021\/acs.jmedchem.2c00094","article-title":"On the Utility of Chemical Strategies to Improve Peptide Gut Stability","volume":"65","author":"Kremsmayr","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1021\/mp500809f","article-title":"Toward Oral Delivery of Biopharmaceuticals: An Assessment of the Gastrointestinal Stability of 17 Peptide Drugs","volume":"12","author":"Wang","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11154-022-09735-8","article-title":"A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes","volume":"23","author":"Aroda","year":"2022","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0165-6147(02)02072-2","article-title":"Mammalian peptide transporters as targets for drug delivery","volume":"23","author":"Daniel","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev.physiol.66.032102.144149","article-title":"Molecular and Integrative Physiology of Intestinal Peptide Transport","volume":"66","author":"Daniel","year":"2004","journal-title":"Annu. Rev. Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Wang, C., Chu, C., Ji, X., Luo, G., Xu, C., He, H., Yao, J., Wu, J., Hu, J., and Jin, Y. (2022). Biology of Peptide Transporter 2 in Mammals: New Insights into Its Function, Structure and Regulation. Cells, 11.","DOI":"10.3390\/cells11182874"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0928-0987(00)00163-9","article-title":"Membrane transporters","volume":"11","author":"Lee","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Bajraktari-Sylejmani, G., Von Linde, T., Burhenne, J., Haefeli, W.E., Sauter, M., and Weiss, J. (2022). Evaluation of PepT1 (SLC15A1) Substrate Characteristics of Therapeutic Cyclic Peptides. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081610"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1517\/17425255.4.7.923","article-title":"Intestinal efflux transporters and drug absorption","volume":"4","author":"Murakami","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1021\/js980082d","article-title":"Role of P-Glycoprotein and Cytochrome P450 3A in Limiting Oral Absorption of Peptides and Peptidomimetics","volume":"87","author":"Wacher","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jconrel.2020.08.005","article-title":"Engineered albumin-functionalized nanoparticles for improved FcRn binding enhance oral delivery of insulin","volume":"327","author":"Azevedo","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"213ra167","DOI":"10.1126\/scitranslmed.3007049","article-title":"Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery","volume":"5","author":"Pridgen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41579-023-00969-0","article-title":"The gut microbiota and its biogeography","volume":"22","author":"McCallum","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Allam-Ndoul, B., Castonguay-Paradis, S., and Veilleux, A. (2020). Gut Microbiota and Intestinal Trans-Epithelial Permeability. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176402"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1848158","DOI":"10.1080\/19490976.2020.1848158","article-title":"Gut Bacteroides species in health and disease","volume":"13","author":"Zafar","year":"2021","journal-title":"Gut Microbes"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1053\/j.gastro.2022.07.004","article-title":"Altered Gut Microbiome Composition and Function Are Associated With Gut Barrier Dysfunction in Healthy Relatives of Patients With Crohn\u2019s Disease","volume":"163","author":"Leibovitzh","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1007\/s10620-023-08122-w","article-title":"Intestinal Barrier Dysfunction in Inflammatory Bowel Disease: Underpinning Pathogenesis and Therapeutics","volume":"68","author":"Dunleavy","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1749-6632.2009.04062.x","article-title":"Epithelial Tight Junctions in Intestinal Inflammation","volume":"1165","author":"Schulzke","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1590\/S0100-879X2010007500020","article-title":"Tumor necrosis factor alpha increases epithelial barrier permeability by disrupting tight junctions in Caco-2 cells","volume":"43","author":"Cui","year":"2010","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s10620-011-1688-9","article-title":"Increase in the tight junction protein claudin-1 in intestinal inflammation","volume":"56","author":"Poritz","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1089\/ars.2011.3892","article-title":"Epithelial Barriers in Intestinal Inflammation","volume":"15","author":"John","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.4049\/jimmunol.171.11.6164","article-title":"Proinflammatory Cytokines Disrupt Epithelial Barrier Function by Apoptosis-Independent Mechanisms","volume":"171","author":"Bruewer","year":"2003","journal-title":"J. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.bbamem.2008.08.027","article-title":"Cytokine regulation of tight junctions","volume":"1788","author":"Capaldo","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e977176","DOI":"10.4161\/21688370.2014.977176","article-title":"Claudin-2 as a mediator of leaky gut barrier during intestinal inflammation","volume":"3","author":"Luettig","year":"2015","journal-title":"Tissue Barriers"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"G367","DOI":"10.1152\/ajpgi.00173.2003","article-title":"TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation","volume":"286","author":"Ma","year":"2004","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0016-5085(98)70155-6","article-title":"Measurement of Gastrointestinal Motility in the GI Laboratory","volume":"115","author":"Camilleri","year":"1998","journal-title":"Gastroenterology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4103\/0250-474X.42967","article-title":"Protein and Peptide Drug Delivery: Oral Approaches","volume":"70","author":"Shaji","year":"2008","journal-title":"Indian J. Pharm. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Karsdal, M.A., Byrjalsen, I., Riis, B.J., and Christiansen, C. (2008). Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: The effect of water and timing of meal intake on oral delivery of Salmon Calcitonin. BMC Clin. Pharmacol., 8.","DOI":"10.1186\/1472-6904-8-5"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3109\/00365529709002989","article-title":"Gastrointestinal Motility Disorders in Patients with Inactive Crohn\u2019s Disease","volume":"32","author":"Annese","year":"1997","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2125.2009.03371.x","article-title":"Influence of food intake on the bioavailability and efficacy of oral calcitonin","volume":"67","author":"Karsdal","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/0091270008330160","article-title":"Effect of Food on the Pharmacokinetics and Pharmacodynamics of an Oral Ghrelin Agonist (ARD-07) in Healthy Subjects","volume":"49","author":"MacLean","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2012-1179","article-title":"Oral Octreotide Absorption in Human Subjects: Comparable Pharmacokinetics to Parenteral Octreotide and Effective Growth Hormone Suppression","volume":"97","author":"Tuvia","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"105509","DOI":"10.1016\/j.ejps.2020.105509","article-title":"Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers","volume":"154","author":"Fattah","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"113925","DOI":"10.1016\/j.addr.2021.113925","article-title":"Formulation strategies to improve the efficacy of intestinal permeation enhancers","volume":"177","author":"Maher","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.biomaterials.2012.10.003","article-title":"Transferrin receptor specific nanocarriers conjugated with functional 7peptide for oral drug delivery","volume":"34","author":"Du","year":"2013","journal-title":"Biomaterials"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"13544","DOI":"10.1073\/pnas.1206924109","article-title":"Mass spectrometry study of a transferrin-based protein drug reveals the key role of protein aggregation for successful oral delivery","volume":"109","author":"Bobst","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Yong, J.M., Mantaj, J., Cheng, Y., and Vllasaliu, D. (2019). Delivery of Nanoparticles across the Intestinal Epithelium via the Transferrin Transport Pathway. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11070298"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1091\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:11:21Z","timestamp":1788142281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":80,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pharmaceutics18091091"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18091091","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]}}}